What the FDA labels say about taking them together
Bupropion and cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide's FDA label of February 3, 2025 names bupropion in its drug interactions section; the bupropion labels PlainMeds reads (4) do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide. The cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label: “Careful dosage titration of the antidepressant and monitoring for antidepressant response are recommended when coadministered with GENVOYA.”
Check it at the source: the bupropion FDA label on DailyMed (effective June 21, 2024); the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide FDA label on DailyMed (effective February 3, 2025, Gilead Sciences, Inc.).
What does the bupropion label say about cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide?
Bupropion's label (effective June 21, 2024) and its 3 other brand-application labels do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (BUPROPION HYDROCHLORIDE), Epic Pharma LLC, effective June 21, 2024 (SPL set 9fb44e96-6160-4a4a-90cb-91764c0dcd89), via openFDA; the full label on DailyMed
What does the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label say about bupropion?
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label, drug interactionsConcomitant Drug Class/Drug Name: Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs) e.g., paroxetine Tricyclic Antidepressants (TCAs) e.g., amitriptyline desipramine imipramine nortriptyline bupropion trazodone; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ SSRIs (except sertraline) ↑ TCAs ↑ trazodone; Clinical Comment: Careful dosage titration of the antidepressant and monitoring for antidepressant response are recommended when coadministered with GENVOYA.
Source: FDA drug label (Genvoya), Gilead Sciences, Inc., effective February 3, 2025 (SPL set 34784acf-15ed-4715-b504-eb30430518e9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Bupropion | Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | |
|---|---|---|
| Labeled for | Depression, Quitting smoking | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0785 per tablet 150 mg tablet | $143.35 per tablet Genvoya tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once